CircRNA Synthesis Market Size, Share and Growth Outlook, 2026

CircRNA Synthesis Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global CircRNA Synthesis Market size is forecast to increase from $241.83 Million in 2026 to $809.37 Million in 2034 at a CAGR of 16.3% between 2026 and 2034.

The CircRNA Synthesis market report provides detailed analysis and outlook of CircRNA Synthesis segments including By Product & Service (Reagents & Kits, Instruments, Synthesis Services), By Synthesis Method (Enzymatic Synthesis, In Vitro Transcription, Chemical & Synthetic Scaffold-Based Methods), By Application (Therapeutics Development, Vaccine Development, Drug Discovery, Diagnostics and Biomarker Discovery, Academic and Basic Research), By End User (Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations, Academic and Research Institutes, Diagnostic Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

CircRNA Synthesis Industry Overview

Clinical-Ready Circular RNA Platforms Accelerating Therapeutic Development

The circRNA synthesis industry is rapidly advancing as biotechnology companies increasingly position circular RNA as a next-generation therapeutic modality for gene therapy, cell therapy, and precision medicine applications. A major industry milestone was highlighted by Therorna Inc., which presented clinical-ready circRNA technologies at the American Society of Gene & Cell Therapy Annual Meeting. The company showcased preclinical data for its lead in vivo CAR-T candidate, TI-0032, which utilizes a scarless and splint-free circRNA payload combined with a T-cell-targeted lipid nanoparticle delivery system. This platform is designed to enable in vivo generation of CAR-T therapies for autoimmune disease treatment without the complexity associated with conventional ex vivo cell engineering. The advancement demonstrates how circular RNA technologies are expanding beyond protein replacement applications into sophisticated immune cell programming and targeted therapeutic interventions. As pharmaceutical developers seek more durable and efficient RNA-based platforms, circRNA synthesis technologies are emerging as critical components of next-generation biologic development.

Investment Activity Expanding Research Pipelines and Disease Applications

The circRNA synthesis industry is attracting substantial investment as companies broaden their therapeutic development strategies. Circio secured a significant funding round to accelerate advancement of its circular RNA platform and expand research across multiple disease areas. While cardiology remains a primary development focus, the company is actively extending its pipeline into ophthalmology, central nervous system disorders, and in vivo CAR-T applications. This diversification highlights the growing confidence in circular RNA as a versatile therapeutic platform capable of addressing a broad spectrum of complex diseases. The increasing allocation of capital toward circRNA research reflects industry recognition of its potential advantages, including enhanced molecular stability, prolonged protein expression, and reduced immunogenicity compared with traditional linear messenger RNA technologies. As investment continues to flow into the sector, research programs are expected to accelerate across both rare and common disease indications.

Manufacturing Innovations Enhancing Therapeutic-Grade RNA Quality

Manufacturing optimization remains a central focus within the circRNA synthesis industry as developers work to achieve the purity and consistency required for clinical and commercial applications. Recent scientific advances in back-splicing optimization have significantly improved the efficiency of circular RNA production. Techniques such as high-performance liquid chromatography (HPLC) purification and RNase R treatment are increasingly being incorporated into manufacturing workflows to remove residual linear RNA precursors and other impurities. These innovations substantially enhance product purity, molecular stability, and batch-to-batch consistency, which are critical requirements for therapeutic-grade circRNA. By minimizing contamination and improving production reliability, advanced purification technologies are helping establish scalable manufacturing frameworks capable of supporting future clinical trials and commercial RNA therapeutics. The continued refinement of synthesis and purification processes is strengthening the foundation for broader adoption of circular RNA across the biotechnology and pharmaceutical industries.

CircRNA Synthesis Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global CircRNA Synthesis market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Thermo Fisher Scientific Inc., GenScript Biotech Corporation, TriLink BioTechnologies (Maravai LifeSciences), Merck KGaA (Sigma-Aldrich), Orna Therapeutics, Laronde (Senda Biosciences), Therorna Inc., CirCode Biotech, Horizon Discovery (Revvity, Inc.), Takara Bio Inc.. The CircRNA Synthesis market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the CircRNA Synthesis industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth CircRNA Synthesis Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by CircRNA Synthesis companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional CircRNA Synthesis markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

CircRNA Synthesis Market Competitive Benchmarking and Company Analysis

Leading companies in CircRNA Synthesis industry include- Thermo Fisher Scientific Inc., GenScript Biotech Corporation, TriLink BioTechnologies (Maravai LifeSciences), Merck KGaA (Sigma-Aldrich), Orna Therapeutics, Laronde (Senda Biosciences), Therorna Inc., CirCode Biotech, Horizon Discovery (Revvity, Inc.), Takara Bio Inc.. The CircRNA Synthesis market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US CircRNA Synthesis Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the CircRNA Synthesis market remains one of the strongest-performing segments in the country.
The US CircRNA Synthesis Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US CircRNA Synthesis market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across CircRNA Synthesis industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian CircRNA Synthesis markets

Canada's strong CircRNA Synthesis sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian CircRNA Synthesis market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany CircRNA Synthesis Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest CircRNA Synthesis market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of CircRNA Synthesis population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany CircRNA Synthesis industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the CircRNA Synthesis market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support CircRNA Synthesis sales through 2034

France CircRNA Synthesis companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK CircRNA Synthesis Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of CircRNA Synthesis distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China CircRNA Synthesis Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China CircRNA Synthesis market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of CircRNA Synthesis industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese CircRNA Synthesis industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India CircRNA Synthesis Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian CircRNA Synthesis market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil CircRNA Synthesis market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa CircRNA Synthesis Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

CircRNA Synthesis Market Segmentation

By Product & Service
Reagents & Kits
Instruments
Synthesis Services
By Synthesis Method
Enzymatic Synthesis
In Vitro Transcription
Chemical & Synthetic Scaffold-Based Methods
By Application
Therapeutics Development
Vaccine Development
Drug Discovery
Diagnostics and Biomarker Discovery
Academic and Basic Research
By End User
Pharmaceutical and Biotechnology Companies
Contract Development and Manufacturing Organizations
Academic and Research Institutes
Diagnostic Laboratories

Top Companies in CircRNA Synthesis Industry

Thermo Fisher Scientific Inc.
GenScript Biotech Corporation
TriLink BioTechnologies (Maravai LifeSciences)
Merck KGaA (Sigma-Aldrich)
Orna Therapeutics
Laronde (Senda Biosciences)
Therorna Inc.
CirCode Biotech
Horizon Discovery (Revvity, Inc.)
Takara Bio Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025